Donnemab Alzheimer’s Hope Blocked
- Despite showing promise in slowing the progression of Alzheimer's disease,Donanemab,marketed as Kisunla,has not received approval from the European Medicines Agency (EMA) for use within the European Union.
- Developed by Eli Lilly, Donanemab has demonstrated a 60% reduction in the progression of Alzheimer's disease in patients experiencing early stages of the condition, according to clinical trial...
- Data presented at the Alzheimer's Association International Conference (AAIC) in 2023, and concurrently published in the Journal of the American medical Association (JAMA), underscored the drug's potential to...
EU Holds Off on Approving Donanemab for Alzheimer’s Treatment
Table of Contents
- EU Holds Off on Approving Donanemab for Alzheimer’s Treatment
- Donanemab and Alzheimer’s Treatment: An Expert Q&A
- What is donanemab and What is it Designed to Do?
- Has Donanemab Been Approved for use in the EU?
- Why Has the EMA Not Approved Donanemab?
- What Kind of Results Did donanemab Show in Clinical Trials?
- how Does the EMA Evaluate Drugs for Approval?
- What are the Possible Side Effects of Donanemab?
- How Does the EU’s Stance Compare to Approvals in Other Countries?
- what Other Alzheimer’s Medications are Being Considered in the EU?
- What Role Does the European Commission Play in Drug Approval?
- Can You Summarize the Key Differences and Similarities Between Donanemab and Lecanemab?
Despite showing promise in slowing the progression of Alzheimer’s disease,Donanemab,marketed as Kisunla,has not received approval from the European Medicines Agency (EMA) for use within the European Union. This decision contrasts wiht approvals granted in the United States, Japan, China, and the United Kingdom.
Donanemab Demonstrates Potential in slowing Alzheimer’s Progression
Developed by Eli Lilly, Donanemab has demonstrated a 60% reduction in the progression of Alzheimer’s disease in patients experiencing early stages of the condition, according to clinical trial results. The findings stem from the Phase 3 Trailblazer-Alz 2 clinical study.
Data presented at the Alzheimer’s Association International Conference (AAIC) in 2023, and concurrently published in the Journal of the American medical Association (JAMA), underscored the drug’s potential to slow cognitive and functional decline in early-stage Alzheimer’s patients.
EMA cites Safety Concerns in Rejecting Approval
The EMA’s decision to withhold approval centers on concerns that the potential benefits of Donanemab do not outweigh the risks.According to the EMA, possible side effects, including brain edema and hemorrhaging, pose too important a threat to patients.
The European authority,headquartered in Amsterdam,emphasized the severity of these potential side effects as the primary reason for its reluctance to recommend the drug’s use within the EU.
Global Approvals Contrast EU Stance
While the EMA remains cautious,Donanemab has already been approved for use in the United States,Japan,China,and the United Kingdom. The drug is not a cure for Alzheimer’s, nor does it halt the disease entirely. Instead,it aims to slow the progression of the disease,notably in its early stages.
Despite these approvals, the EMA remains steadfast in its concerns regarding the potential for severe side effects, maintaining a cautious approach to authorizing the drug within the European Union.
EU Awaits Alzheimer’s Drug Approval
Currently, the European Union has not approved any medication that directly targets the underlying mechanisms of Alzheimer’s disease. Lecanemab,another antibody-based treatment,received a positive opinion from the EMA but still awaits a final decision from the European Commission.
Lecanemab initially faced similar scrutiny from the EMA, with concerns raised that the risks outweighed the potential benefits. though, following revisions to the approval submission and a reassessment of the data, the agency concluded that, for a specific subset of patients, the benefits could outweigh the risks.
The reassessment involved a more detailed analysis of patient subgroups, which had not been adequately considered during the initial evaluation.
Donanemab and Alzheimer’s Treatment: An Expert Q&A
This article explores the current status of Donanemab, a promising Alzheimer’s treatment, in the European Union, answering key questions about its approval status, effectiveness, and potential risks. We’ll break down the complexities of this drug and the European Medicines Agency’s (EMA) decision-making process.
What is donanemab and What is it Designed to Do?
Donanemab, also known as Kisunla, is an antibody-based treatment developed by Eli Lilly. It’s designed to slow the progression of Alzheimer’s disease, primarily in the early stages of the condition. It’s critically important to note that it is indeed not a cure and doesn’t halt the disease entirely.
Has Donanemab Been Approved for use in the EU?
No, Donanemab has not been approved for use within the European Union. The European Medicines Agency (EMA) has withheld approval, despite its approvals in othre countries, including the united States, Japan, China, and the United Kingdom.
Why Has the EMA Not Approved Donanemab?
The primary reason for the EMA’s cautious stance is concern over potential side effects.The EMA believes that the risks associated with Donanemab, such as brain edema (swelling of the brain) and hemorrhaging, may outweigh the potential benefits for patients.
What Kind of Results Did donanemab Show in Clinical Trials?
Clinical trial results, specifically from the Phase 3 trailblazer-Alz 2 study, indicated that Donanemab could achieve a 60% reduction in the progression of Alzheimer’s disease in patients experiencing early stages. Data presented at the Alzheimer’s Association International Conference (AAIC) in 2023 and published in JAMA, supported these findings, showing the drug’s potential to reduce both cognitive and functional decline.
how Does the EMA Evaluate Drugs for Approval?
The EMA carefully assesses the safety and efficacy of medications before making a suggestion. They consider various factors, including clinical trial data, potential side effects, the severity of the condition, and the availability of other treatments. In Donanemab’s case, the EMA weighed the benefits against the risks of serious side effects and resolute that the risks currently outweigh the benefits.
What are the Possible Side Effects of Donanemab?
the EMA has cited potential side effects, including brain edema and hemorrhaging, as significant concerns. These are serious potential complications that the EMA considers during its approval process.
How Does the EU’s Stance Compare to Approvals in Other Countries?
While the EMA has not approved Donanemab, it has been approved and is available in the United States, Japan, China, and the United Kingdom. This difference in approach highlights the EMA’s cautious approach to drug approvals, especially when dealing with perhaps severe side effects.
what Other Alzheimer’s Medications are Being Considered in the EU?
The EU is also evaluating other antibody-based treatments like Lecanemab. Even though Lecanemab received a positive opinion from the EMA, approval awaits a final decision from the European Commission. Similar to Donanemab, Lecanemab also faced scrutiny over its risk-benefit profile, and the agency conducted a reassessment of the patient subgroups.
What Role Does the European Commission Play in Drug Approval?
The EMA provides opinions on whether or not a medicine should be approved. However, the final decision on whether a drug can be marketed throughout the EU rests with the European Commission.
Can You Summarize the Key Differences and Similarities Between Donanemab and Lecanemab?
Here’s a comparison of Donanemab and Lecanemab based on the provided information:
| Feature | Donanemab (Kisunla) | Lecanemab |
|---|---|---|
| Developer | Eli Lilly | *Not Specified in Source* |
| EU Approval Status | not Approved | Positive opinion from EMA; awaiting final decision from European Commission |
| Mechanism | Antibody-based treatment | Antibody-based treatment |
| Primary Goal | Slow progression of Alzheimer’s disease, mainly in early stages | *Implied: Slow progression of Alzheimer’s disease* |
| Reported Efficacy | 60% reduction in progression in early stages (clinical trials) | *Implied: comparable efficacy; details not given* |
| Major Concerns | Brain edema, hemorrhaging (cited by EMA) | *Implied similar safety profile* |